Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Among 10 premenopausal women with Metabolic Syndrome:
Specific Aim 1: Compare the effects of acute fat feeding on flow mediated dilation (FMD) as measured by brachial artery reactivity among three fat challenges (saturated fat vs. monounsaturated fat (MUFA) vs. polyunsaturated fat (PUFA)at 4 hours post feeding. Hypothesis Saturated fat feeding will impair FMD but MUFA and PUFA feeding will not.
Specific Aim 2: Compare the effects of acute feeding on vascular inflammation as measured by VCAM and sICAM among three fat challenges at 3 1/2 hours post feeding.
Hypothesis: Saturated fat feeding will increase vascular inflammation but MUFA and PUFA will not.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| young women with MetS | Experimental |
|
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| fat feeding | Dietary Supplement | Each feeding will consist of 473 mL of nonfat milk and 50 gms oil. The oil will be high in saturated fat, monounsaturated fat or polyunsaturated fat. |
| Measure | Description | Time Frame |
|---|---|---|
| Flow Mediated Dilation at 4 hours post feeding | 4 hours | four hours |
| Measure | Description | Time Frame |
|---|---|---|
| Adhesion molecules (VCAM and sICAM) | 3 1/2 hours |
Not provided
Inclusion Criteria:
Female,
18-50 years of age,
Pre-menopausal,
Weight stable for at least 3 months,
Not planning to lose or gain weight for 3 months,
Meets the following 3/5 criteria for metabolic syndrome:
Exclusion Criteria:
(**) Drugs within the following classifications are exclusionary: Lipid lowering, beta blockers, ACE inhibitors, angiotensin receptor blockers, diuretics, calcium channel blockers, alpha blockers, nitrates, hormone contraception includes patch or oral hormone contraception (Hormone containing IUDs or vaginal rings are okay)
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Pathmaja Paramsothy, MD, MS | University of Washington | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University of Washington | Seattle | Washington | 98104 | United States |
| Type | Date | Date Unknown |
|---|---|---|
| Release | Aug 29, 2012 | |
| Reset | Sep 28, 2012 | |
| Release | Apr 10, 2017 | |
| Reset | Jun 23, 2017 |
Not provided
Not provided
| Release Date | Unrelease Date | Unrelease Date Unknown | Reset Date | MCP Release Number |
|---|---|---|---|---|
| Aug 29, 2012 | Sep 28, 2012 | |||
| Apr 10, 2017 |
| ID | Term |
|---|---|
| D024821 | Metabolic Syndrome |
| ID | Term |
|---|---|
| D007333 | Insulin Resistance |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Jun 23, 2017 |
| D009750 |
| Nutritional and Metabolic Diseases |